Visibility Vol 11 Issue 3 & 4, 2017

Effect of Fluocinolone Acetonide 0.2μg/day (ILUVIEN®) Implant on the Decision to Drive in Patients with Diabetic Macular Edema

The NEI-VFQ questionnaire was administered as part of the FAME phase 3 clinical trials. The driving subscale score (DSS), one of 12 subscale scores derived from the questionnaire, assesses driving difficulty in patients . The fluocinolone acetonide (FAc) 0.2μg/day implant is the only approved treatment for DME that continuously delivers therapy for 36 months with a single administration. This post hoc analysis was conducted to assess the relationship between improvement in visual acuity associated with 0.2μg/day FAc implant treatment and changes in the DSS over time and factors that may contribute to these findings.

Read More
A person helping another person with a reading aide

Well-Being and Mental Health Factors among Informal Caregivers of Individuals with Visual Impairments

Callie Victor, PhD, OTR/L, CLA; Matthew Haase, MS, OTR/L, ATC; Michael Bown; Lindsey Bates, OTR; Michael Centra, OTR/L; Jaclyn Sachleben; Elizabeth Tyson; Michelle Gamber, DrPH; Suleiman Alibhai

View Article
Patient with Stand Magnifier

Stand Magnifier Optical Strategies

Gregg Baldwin, OD

View Article
Man using magnifier on glasses

Characteristics of Older Bioptic Drivers: Effects of Increasing Age on Driving Safety

Bradley E. Dougherty, OD, PhD

Download Article